- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Vitreoretinal Lymphoma
Vitreoretinal Lymphoma, or Vitreous Retinal Lymphoma, is commonly categorized as Primary Intraocular Lymphoma. It is an uncommon type of aggressive non-Hodgkin lymphoma that escalates rapidly and primarily affects the vitreous humor and retina of the eye. Protheragen provides a comprehensive solution to vitreoretinal lymphoma, including diagnostics development, therapeutics development, preclinical research, and animal model development.
Vitreoretinal lymphoma (VRL) is an aggressive intraocular cancer that is remote and rather uncommon. VRL primarily affects primary the vitiligo and the retina of the eye. It is characterized as a type of primary central nervous system lymphoma (PCR-NL) and is of the diffuse large B-cell lymphoma (DLBCL) type. It has rapid advancement and ubiquity that leads to ocular morbidity, which disables vision and sometimes, results with damage to the central nervous system.
Fig.1 Schema of the anatomy of the eye and anatomical classification of intraocular lymphoma (IOL). (Soussain C., et al., 2021)The importance of molecular diagnostics in VRL diagnosis has been tremendous. The detection of the MYD88 mutations, specifically the L265P polymorphism, has emerged as one of the sensitive and specific markers for VRL. Also, PCR analysis of immunoglobulin gene rearrangements can identify monoclonal B-cell populations which aid the diagnosis. Cytologic examination of eye fluids, including vitreous and aqueous humor, remains a cornerstone of diagnostic development. Unusual B cells that express CD20 and kappa/lambda light chain restriction may be found through flow cytometry and immunocytochemistry, which is important for the diagnosis of VRL.
| Therapeutics | Target | Description | Research Stage |
| Methotrexate | Proliferating B-Cells | It is used both locally (intravitally) and systemically to treat VRL. | Approved |
| Rituximab | CD20+ B-Cells | It is administered intravitally or systemically to induce apoptosis in malignant B-cells. | Approved |
| MYD88 Inhibitors | MYD88 Mutations | MYD88 mutations are frequently observed in VRL and contribute to immune evasion and B-cell activation. | Preclinical |
| MicroRNA (miRNA) Modulators | miRNA Pathways | Aberrant miRNA expression is associated with VRL, and modulating miRNA pathways is a potential therapeutic strategy under investigation. | Preclinical |
| CXCL13 Inhibitors | CXCL13 Pathway | CXCL13 is a chemokine involved in B-cell homing and survival in VRL. Inhibitors targeting CXCL13 are being explored for their potential to disrupt the tumor microenvironment and B-cell survival. | Preclinical |
| Interleukin-10 (IL-10) Inhibitors | IL-10 Pathway | Elevated IL-10 levels are associated with VRL. Inhibitors targeting IL-10 or its signaling pathways are being studied for their potential to modulate the immune response and reduce tumor growth. | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen offers comprehensive diagnostics and therapeutic development services for vitreoretinal lymphoma. Our services encompass the development of advanced diagnostic tools, including cytological and molecular techniques, as well as the design and optimization of therapeutic strategies, such as immunotherapy and targeted therapy.
Vitreoretinal lymphoma is a complex and challenging disease that requires a multidisciplinary approach for effective diagnostics and therapeutics development. Protheragen is committed to advancing the field through innovative diagnostics, therapeutics, and preclinical research services, offering comprehensive solutions to meet the needs of our clients. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.